Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep;24(9):485-496.
doi: 10.1007/s11882-024-01167-5. Epub 2024 Aug 6.

Oral Janus Kinase Inhibitors in Pediatric Atopic Dermatitis

Elsy M Navarrete-Rodríguez #  1 , Désirée Larenas-Linnemann #  2   3 , Helena Vidaurri de la Cruz  4 , Jorge A Luna-Pech  5 , Esther Guevara Sanginés  6
Affiliations
Review

Oral Janus Kinase Inhibitors in Pediatric Atopic Dermatitis

Elsy M Navarrete-Rodríguez et al. Curr Allergy Asthma Rep. 2024 Sep.

Abstract

Purpose of review: To analyze the efficacy and safety of Janus kinase inhibitors (JAKi) in the treatment of pediatric AD.

Recent findings: Adolescents with moderate and severe atopic dermatitis (AD) need systemic therapies, as stated several recent practice guidelines. (JAKi) have shown their efficacy in the treatment of adult AD, however, there is a lack of information concerning efficacy and safety of their use in pediatric AD. We found that the JAKi's abrocitinib (ABRO), baricitinib (BARI), and upadacitinib (UPA), are all an effective treatment option with a very fast onset of action for adolescents with moderate-to-severe AD. BARI was not effective in children between 2 and 10 years with moderate-to-severe AD. Fortunately, major safety issues with JAKi in adolescents with AD have not been documented in the trials, so far, contrasting with the reports in adults with AD, where these events have very rarely occurred. There are some reports of herpes zoster (HZ) infection in adolescents on JAKi, but it is not a major safety concern. Acne is a relatively common AE with UPA in adolescents; however, it is responsive to standard treatment. This review will help the clinician to choose among the JAKi according to the needs and clinical features of patients with moderate and severe AD. In the following years, with the advent of new biologicals and JAKi, these therapies will fall into place in each phase of the evolution of patients with AD.

Keywords: Abrocitinib; Adolescents; Atopic dermatitis; Baricitinib; Oral JAK inhibitor; Upadacitinib.

PubMed Disclaimer

References

    1. Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: Data from the 2003 National Survey of Children’s Health. J Invest Dermatol. 2011;131(1):67–73. - DOI - PubMed
    1. Langan S, Mulick AR, Rutter CE, Silverwood RJ, Asher I, Garcia-Marcos L, et al. Trends in eczema prevalence in children and adolescents: A Global Asthma Network Phase I Study. Clin Exp Allergy. 2023;53:337–52. - DOI - PMC
    1. Navarrete-Rodriguez EM, Del-Rio-Navarro BE, Reyes Noriega N, Berber A, Merida Palacio V, Garcia-Almaraz R, et al. Have the prevalence of eczema symptoms increased in the Mexican pediatric population? Prevalence and associated factors according to Global Asthma Network Phase I. World Allergy Organ J. 2022;15(11):100710. - DOI - PubMed - PMC
    1. Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema: Part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–31. - DOI - PubMed
    1. Larenas-Linnemann D, Rincon-Perez C, Luna-Pech JA, Macias-Weinmann A, Vidaurri-de la Cruz H, Navarrete-Rodriguez EM, et al. Guidelines on atopic dermatitis for Mexico (GUIDAMEX): Using the ADAPTE methodology. Gac Med Mex. 2023;158(Supplement 2):1–116. - PubMed

MeSH terms

LinkOut - more resources